Hepatoprotective activity of CrPic against alloxan-induced hepatotoxicity in mice

This study focused on oxidation hepatic injury induced by alloxan treatment in mice and the hepatoprotective effect of chromium picolinate (CrPic) against such injury. The mice were randomly divided into three groups (control, alloxan, and CrPic). The CrPic mice were given Cr(3+) (40 μg/kg bm/day), and other mice were given equivalent intragastric doses of water every day. After 4 weeks, the groups alloxan and CrPic were treated with alloxan (40 mg/kg/day) through intraperitoneal injection daily for 6 days. Biochemical and enzymatic characteristics were assayed in these animals. The MDA levels of the control and CrPic groups were 33.93 % and 28.45 % lower, respectively, than that of the alloxan group. The levels of superoxide dismutase (SOD) and GSH-Px in the alloxan group were 15.30 % and 15.69 % higher, respectively,than those of the control group. Both the SOD and GSH-Px levels of the control and CrPic groups were about the same. Levels of CuZnSOD mRNA of the control and CrPic groups were 0.27 fold and 1.03 fold lower than in the alloxan group. The transcription levels of GSH-Px in the control and CrPic groups were 1.57 fold and 0.99 fold below those of the alloxan group. These results show that significant hepatic injury can be induced by alloxan treatment in mice; in addition, CrPic may be useful in health products meant to treat human liver disease.